Marie-Nicole Theodoraki: Early detection of response in head and neck cancer patients
“My team and I have detected an EV based signature for very early cancer detection. Compared to cell free DNA we have the advantage of detecting cancer on an early stage ! This way therapy outcomes and 5-year OS can be significantly increased in the future.
Head and neck squamous cell carcinomas are highlighted immune suppressive malignancies. Despite various treatment regimens available, survival rates are very low also due to high numbers of recurrences. Here we show for the first time, that PD-L1 on small extracellular in a longitudinal study of head and neck cancer patients vesicles is a metric for recurrence-free survival and can be used to identify a recurrence months before recurrence is clinically visible.”
Authors: M-N Theodoraki, S Laban, E K Jackson, R Lotfi, P J Schuler, C Brunner, T K Hoffmann, T L Whiteside, L Hofmann.
Marie-Nicole Theodoraki is a Senior Consultant specializing in ENT (Ear, Nose, and Throat) and Head and Neck Surgery and Principal Investigator in Oncoimmunology at Klinikum rechts der Isar and at the University of Ulm. Her expertise includes studying exosomes in head and neck cancer as liquid biomarkers for diagnostic and therapeutic applications. She is also involved in entrepreneurship through the startup BIOEXOTEC, which aims to advance innovations in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023